The Brocade 3 Study is a breast cancer research study that evaluates an investigational drug combination in subjects with HER2- metastatic or locally advanced BRCA-associated breast cancer for which local therapy (surgery or radiation) is not appropriate. If you are unsure if your breast cancer is BRCA-associated, genetic testing might be available. This phase III clinical research study is evaluating the safety and effectiveness of the study medication in combination with Carboplatin and Paclitaxel compared to the combination of Carboplatin and Paclitaxel without the study medication.
Approximately 270 men and women will participate in this study worldwide.
For more information on participation in the Brocade 3 Study, click here to see a list of participating physicians. Call 844-893-5525 or email AbbVie@emergingmed.com to see if you may qualify.
Participants will receive investigational drug combination in cycles that are 28 days in length. Study visits will occur on days 1, 8 and 15 of each cycle. After every 9 weeks of study treatment, your tumor(s) will be measured by a CT or MRI scan to see if it (they) has become smaller, stayed the same, or grown (progressed).
Participation in this study will last approximately 6 to 12 months and include approximately 20 study visits to the research center. Study related visits will include physical exams, routine blood tests, ECGs and radiologic scans. Compensation for travel may also be provided.
For more information on participation in the Brocade 3 Study, click here to see if you or a loved one can participate! Call 844-893-5525 or email AbbVie@emergingmed.com to see if you may qualify.